Panitumumab in Patients with KRAS Wild-Type Colorectal Cancer after Progression on Cetuximab

PURPOSE: Cetuximab and panitumumab are monoclonal antibodies that target the epidermal growth factor receptor (EGFR) and are approved for the treatment of patients with KRAS wild-type meta-static colorectal cancer. There are no data that describe the activity of panitumumab in patients with progress...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Wadlow, Raymond C., Hezel, Aram F., Abrams, Thomas A., Blaszkowsky, Lawrence S., Fuchs, Charles S., Kulke, Matthew H., Kwak, Eunice L., Meyerhardt, Jeffrey A., Ryan, David P., Szymonifka, Jackie, Wolpin, Brian M., Zhu, Andrew X., Clark, Jeffrey W.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: AlphaMed Press 2012
Gaiak:
Clinical Trial Reports
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3267814/
https://ncbi.nlm.nih.gov/pubmed/22210091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0452
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak